US Stock Futures Signal Higher Start On Wall Street

Loading...
Loading...
Pre-open movers
US stock futures traded higher in early pre-market trade. Data on weekly jobless claims will be released at 8:30 a.m. ET, while the Markit PMI services index for December will be released at 9:45 a.m. ET. The general conditions index of the Philadelphia Fed's Survey for December and the Conference Board's index of leading indicators for November will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average jumped 181 points to 17,473.00, while the Standard & Poor's 500 index futures rose 22.20 points to 2,030.40. Futures for the Nasdaq 100 index climbed 53.25 points to 4,212.75.
A Peek Into Global Markets
European markets were higher today, with the Spanish Ibex Index gaining 2.69%, STOXX Europe 600 Index rising 2.07%. German DAX 30 index climbed 2.08%, French CAC 40 Index gained 2.57% and London's FTSE 100 Index rose 0.98%. In Asian markets, Japan's Nikkei Stock Average rose 2.32%, Hong Kong's Hang Seng Index climbed 1.09%, China's Shanghai Composite Index fell 0.11% and India's Sensex jumped 1.56%.
Broker Recommendation
Analysts at Longbow Research upgraded
Joy Global, Inc.JOY
from Underperform to Neutral. The price target for Joy Global is set to $50. Joy Global's shares closed at $46.14 yesterday.
Breaking news
  • Winnebago Industries, Inc. WGO reported weaker-than-expected fiscal first-quarter earnings. To read the full news, click here.
  • Akers Biosciences, Inc. AKER has entered into its first European distribution agreements since the installment of its international vice president in August 2014. To read the full news, click here.
  • TetraLogic Pharmaceuticals Corporation TLOG today announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with early stage cutaneous T cell lymphoma ("CTCL"). To read the full news, click here.
  • BioCryst Pharmaceuticals, Inc., BCRX today announced that it has dosed the first patient in OPuS-2 (Oral ProphylaxiS-2), a blinded, randomized, placebo-controlled clinical trial of orally-administered BCX4161 in patients with hereditary angioedema (HAE). To read the full news, click here.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsLongbow ResearchUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...